Boulevard Bio launches with $65M from Deerfield Management, advancing BLVD101 (IgAN bispecific), BLVD201 from METiS TechBio, and BLVD301. CEO Mahesh Karande seeks additional investors.
Mahesh Karande, Boulevard Bio CEO
August 12, 2026 06:30 AM EDT
Boulevard Bio dreams big in immunology with $65M, sights on Vera's IgAN drug
Though it’s no longer unusual for a startup to emerge with an investigational drug from China, an immunology biotech is adding that …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Co-founded by pioneering researcher Georg Schett and ex-Sanofi CSO Frank Nestle, the startup is advancing a trio of multifaceted…
Boulevard Bio Launches with $65 Million from Deerfield and World-Class Founders to Advance Precision Immunology Pipeline
Hong Kong-listed AI-driven drug delivery innovation company Metis TechBio Co Ltd said on Tuesday it had granted Boulevard Bio, an…
Claris Bio has appointed veteran CEO Stephen Brady to lead advanced development of what it hopes to be the first drug therapy for…
The biotech, co-founded by Sofinnova Partners and a former Sanofi immunology R&D head, is testing new biologics against common…
Parabilis Medicines prices a $670M IPO — the biggest biotech Nasdaq debut ever — to fund its experimental desmoid-tumor drug…
